SentreHeart said today that the German Institute for the Hospital Remuneration System granted renewed Status 1 to its Lariat and Eclipse left atrial appendage closure devices.
The coverage will allow 50 hospitals under the NUB1 innovation program to negotiate for reimbursement to cover costs for treating patients with the Lariat for LAAC when such a procedure is a suitable alternative to anticoagulation. The decision is valid for 1 year and can be renewed by application, the Redwood City, Calif.-based company said.
“We are very pleased with the NUB renewal and the robust number of applications for 2017. This is validation of the growing interest by German clinicians utilizing the LARIAT as a non-implant solution for LAA closure,” prez & CEO Russ Seiber said in a prepared statement.
The company’s Lariat LAAC device won CE Mark approval in the European Union in October 2015.
The device is commonly used for the ligation of the LAA as an adjunctive treatment to ablation in patients with persistent atrial fibrillation, the company said. Closing off the LAA prevents blood clots from forming that could later cause stroke in AF patients.